Get the Stockscreener App
5.05
6.99%
0.33
After Hours:
5.04
-0.010
-0.20%
Alumis Inc stock is traded at $5.05, with a volume of 1.20M.
It is up +6.99% in the last 24 hours and up +13.74% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$4.72
Open:
$4.75
24h Volume:
1.20M
Relative Volume:
1.93
Market Cap:
$489.24M
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.1884
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
+10.75%
1M Performance:
+13.74%
6M Performance:
+0.40%
1Y Performance:
-57.99%
1-Day Range:
$4.585
$5.10
1-Week Range:
$4.40
$5.10
52-Week Range:
$2.7601
$12.29
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
5.05 | 491.18M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.20 | 103.89B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.74 | 69.11B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.70 | 58.49B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
869.83 | 52.62B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
191.92 | 40.46B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Is a relief rally coming for Alumis Inc. holders2025 Market Sentiment & Expert Verified Movement Alerts - newser.com
Will Alumis Inc. continue its uptrendMarket Sentiment Report & Long-Term Safe Investment Plans - newser.com
Momentum divergence signals in Alumis Inc. chartWeekly Gains Summary & Technical Buy Zone Confirmations - newser.com
Real time scanner hits for Alumis Inc. explainedTake Profit & Risk Controlled Stock Pick Alerts - newser.com
Is Alumis Inc. a candidate for recovery play2025 Institutional Moves & Weekly Breakout Opportunity Watchlist - newser.com
How to manage a losing position in Alumis Inc.July 2025 Rallies & Detailed Earnings Play Strategies - newser.com
Alumis Inc expected to post a loss of 92 cents a shareEarnings Preview - TradingView
Will Alumis Inc. stock remain a Wall Street favoriteTrade Exit Summary & High Accuracy Trade Alerts - newser.com
Is Alumis Inc. stock positioned for long term growthJuly 2025 Breakouts & Verified Entry Point Signals - newser.com
Will Alumis Inc. stock benefit from sector rotationJuly 2025 Earnings & Daily Risk Controlled Trade Plans - newser.com
Is Alumis Inc. stock a safe buy before earnings2025 Biggest Moves & High Accuracy Swing Trade Signals - Fundação Cultural do Pará
Alumis (ALMS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Will Alumis Inc. stock benefit from upcoming earnings reportsJuly 2025 Market Mood & Target Return Focused Picks - newser.com
Alumis to Participate in Upcoming November Investor Conferences - The Manila Times
Alumis (Nasdaq: ALMS) schedules investor conference webcasts, replays for 90 days - Stock Titan
Analyzing drawdowns of Alumis Inc. with statistical toolsJuly 2025 WrapUp & Daily Profit Focused Stock Screening - newser.com
Will Alumis Inc. outperform the marketJuly 2025 Institutional & Consistent Profit Alerts - newser.com
Tools to assess Alumis Inc.’s risk profile2025 Volume Leaders & Low Drawdown Momentum Trade Ideas - newser.com
Why Alumis Inc. stock is recommended by analystsJuly 2025 Macro Moves & Entry Point Confirmation Signals - newser.com
Chart based exit strategy for Alumis Inc.2025 Trade Ideas & Real-Time Stock Movement Alerts - newser.com
What insider trading reveals about Alumis Inc. stockWeekly Profit Report & AI Enhanced Execution Alerts - Fundação Cultural do Pará
Will Alumis Inc. stock outperform value stocksInsider Selling & Verified Short-Term Trading Plans - Fundação Cultural do Pará
How sustainable is Alumis Inc. stock dividend payout2025 Winners & Losers & Long-Term Growth Portfolio Plans - Fundação Cultural do Pará
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alumis Inc Stock (ALMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tananbaum James B. | Director |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Labs, LLC | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Labs, LLC | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Capital Management VI | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Capital Management VI | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| AKKARAJU SRINIVAS | Director |
May 05 '25 |
Buy |
4.67 |
160,370 |
749,676 |
3,586,788 |
| AKKARAJU SRINIVAS | Director |
May 02 '25 |
Buy |
4.55 |
159,920 |
727,636 |
3,426,418 |
| Colowick Alan | Director |
Apr 01 '25 |
Buy |
6.97 |
16,104 |
112,309 |
16,104 |
| Colowick Alan | Director |
Apr 02 '25 |
Buy |
7.49 |
2,300 |
17,235 |
18,404 |
| Babler Martin | President, CEO and Chairman |
Apr 01 '25 |
Buy |
6.44 |
15,650 |
100,733 |
106,454 |
0.05%
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):